RecruitingNot ApplicableNCT03401879

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis


Sponsor

Medical University of Vienna

Enrollment

50 participants

Start Date

Feb 1, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men. MS is traditionally diagnosed by the presentation of lesions of the central nervous system, disseminated in time and in space, proven by clinical examination and magnetic resonance imaging. Several anatomical parameters in the eye, both vascular and neural, have been found to be altered in MS patients. Because of its unique optical properties, the eye offers the possibility of the non-invasive assessment of both structural and functional alterations in neuronal tissue. As the neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative changes in the brain are accompanied by structural and possibly also functional changes in the neuro-retina and the ocular vasculature. The current study seeks to test the hypothesis that beside the known anatomical changes, also functional changes can be detected in the retina of patients with MS. For this purpose, flicker light induced hyperemia will be measured in the retina as a functional test to assess the coupling between neural activity and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness and function parameters such as ocular blood flow and retinal oxygenation will be assessed and compared to age and sex matched controls.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how blood vessels and nerve cells in the retina (the back of the eye) work together in people with multiple sclerosis (MS), particularly in those who have had a previous episode of optic nerve inflammation, compared to healthy volunteers. **You may be eligible if...** - You are 18 years or older - You are a non-smoker - You have been diagnosed with relapsing-remitting MS (the most common form) and had an episode of optic nerve inflammation at least one year ago (for the MS group) - OR you are a healthy volunteer with no known serious medical conditions and normal eye health (for the control group) - Your vision is good enough to participate in eye measurements **You may NOT be eligible if...** - You smoke - You have a diagnosis of possible MS (for healthy controls) - You have untreated high blood pressure - You have a personal or family history of epilepsy - You have significant eye disease or wear very strong glasses/contacts (greater than 6 diopters) - You have any other serious medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDynamic Vessel Analyzer (DVA)

Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

DEVICEFourier Domain Doppler Optical Coherence Tomography (FDOCT)

Retinal blood flow will be assessed using FDOCT.

DEVICEOptical coherence tomography (OCT)

Nerve fiber layer thickness and central retinal thickness will be measured using OCT.

DEVICEOptical coherence tomography angiography (OCTA)

Retinal microvasculature will be assessed using OCTA.


Locations(1)

Department of Clinical Pharmacology, Medical University of Vienna

Vienna, Austria, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03401879


Related Trials